Cagrilintide
Also known as: AM833, NN9838, CagriSema (combination)
Key Facts: Cagrilintide
- Category
- Weight Loss
- FDA Status
- Not FDA Approved
- Clinical Status
- Phase 3 Trials - Not yet FDA approved
- Administration
- Subcutaneous injection once weekly
- Typical Dose
- 2.4 mg weekly
- Frequency
- Once weekly
- Evidence Level
- Human Trials
- Duration
- Long-term / chronic use expected
What to Expect
A long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).
Mechanism of Action
Cagrilintide mimics amylin, a hormone co-secreted with insulin from pancreatic beta cells. It activates amylin and calcitonin receptors in the area postrema and nucleus tractus solitarius of the brainstem, enhancing satiety signaling. Unlike GLP-1 agonists, it works through homeostatic and hedonic appetite centers, reducing hunger and promoting earlier meal termination. Also slows gastric emptying to prolong fullness.
Research Summary
REDEFINE 1 Phase 3 trial showed 11.8% weight loss with cagrilintide monotherapy vs 2.3% placebo over 68 weeks. Combined with semaglutide (CagriSema), average weight loss reached 20.4% vs 3.0% placebo. 60% of CagriSema participants achieved ≥20% weight loss, and 23% lost ≥30%. This represents some of the most significant weight loss results seen with any anti-obesity medication.
Dosing Information
Typical Dosingⓘ
Community experience
2.4 mg weekly
1.0-2.4 mg weekly (dose escalation)
Once weekly
Most effective when combined with semaglutide (CagriSema). Works through amylin pathway which is complementary to GLP-1 mechanism. Dose escalation typically used to minimize GI side effects. Not yet commercially available - still in clinical trials.
Research Dosingⓘ
Scientific studies
Doses from clinical trials - not yet approved
Doses from Studies
2.4 mg cagrilintide + 2.4 mg semaglutide weekly
REDEFINE 1 Trial (CagriSema) - Phase 3 - 20.4% weight loss with combination ↗
Duration
Long-term / chronic use expected
Administration
Subcutaneous injection once weekly
Timing & Administration
Best Time to Take
Any consistent time weekly
Once weekly
Food Recommendation
With or without food
Why This Timing?
Once-weekly injection provides sustained amylin receptor activation. Timing is flexible but should be consistent week to week.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Nausea (common, usually transient)
- ●Vomiting
- ●Diarrhea
- ●Constipation
- ●Abdominal pain
- ●Injection site reactions
- ●Decreased appetite
- ●Headache
- ●Dyspepsia
- ●GI events affected 79.6% in CagriSema trials (mostly mild-moderate)
- ●Limited long-term safety data - still in trials
References
Related Peptides
Peptides commonly compared with Cagrilintide or used in similar applications.
Semaglutide
FDAA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. One of the most effective pharmaceutical weight loss interventions available.
Weight LossLiraglutide
FDAAn FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Weight LossRetatrutide
Clinical TrialsA triple agonist targeting GLP-1, GIP, and glucagon receptors. Represents the next evolution beyond dual agonists like tirzepatide, showing unprecedented weight loss in trials.
Weight LossOrforglipron
Clinical TrialsAn oral non-peptide GLP-1 receptor agonist. Could provide injection-free alternative to semaglutide and tirzepatide.
Weight LossCagriSema
Clinical TrialsA combination of semaglutide and cagrilintide (amylin analog) in development. Aims to provide superior weight loss through dual mechanisms.
Weight LossSurvodutide
Clinical TrialsA dual GLP-1/glucagon receptor agonist in development for obesity and NASH. Combines appetite suppression with increased energy expenditure.
Weight LossWant updates on Cagrilintide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.